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Xiayun He1, Duanshu Li2, Chaosu Hu1, Zhuoying Wang2, Hongmei Ying1 and Yi Wu2*Abstract
Background: Anaplastic thyroid carcinoma (ATC) is a malignancy with one of the highest fatality rates. We
reviewed our recent clinical experience with intensity modulated radiotherapy (IMRT) combined with surgery and
chemotherapy for the management of ATC.
Methods: 13 patients with ATC who were treated by IMRT in our institution between October 2008 and February
2011, have been analyzed. The target volume for IMRT was planned to include Gross tumor volume (GTV): primary
tumor plus any N + disease (66 Gy/33 F/6.6 W), with elective irradiation of thyroid bed, bilateral level II through VI
and mediastinal lymph nodes to the level of the carina (54-60 Gy). Seven patients received surgical intervention
and eleven patients had chemotherapy.
Results: The median radiotherapy dose to GTV was 60 Gy/30 fractions/6 weeks. The median survival time of the 13
patients was 9 months. The direct causes of death were distant metastases (75%) and progression of the
locoregional disease (25%). Ten patients were spared dyspnea and tracheostomy because their primary neck lesion
did not progress.
Conclusion: The results showed that IMRT combined by surgery and chemotherapy for ATC might be beneficial to
improve locoregional control. Further new therapies are needed to control metastases.
Keywords: Anaplastic thyroid carcinoma, ATC, Intensity modulated radiotherapy, Locoregional control, Distant
metastasesBackground
Anaplastic thyroid carcinoma (ATC) is a rare malignant
tumor and accounts for <5% of all thyroid cancers in in-
cidence, but is responsible for up to 50% of all thyroid
cancer deaths. ATC is very aggressive and can invade
directly into adjacent organs, such as the trachea, larynx,
esophagus, blood vessels and muscle, resulting in suffo-
cation, vocal cord paralysis, dyspnea and/or dysphagia.
Most patients die a few months after diagnosis because
of uncontrolled neck mass and metastases, and long-term
survivors are rare [1-4]. In the dead patients, dyspnea was
the most common cause due to extensive neck mass, and
another cause was metastases [5]. A tracheotomy may
sometimes be performed to solve airway obstruction, but
which also deteriorated the quality of life in the patients.* Correspondence: shzlfl@gmail.com
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reproduction in any medium, provided the orBecause the prognosis for ATC is so poor, all ATC are
classified as stage IV according to International Union
Against Cancer (UICC) staging, regardless of tumor size,
nodal status, and either absence or presence of distant
metastasis. Combined modality therapy with surgery,
chemotherapy and two dimensional or conformal radio-
therapy, have been adopted for ATC [6-9], but the re-
sults have not been satisfactory. Lim et al. [8] reviewed
the treatment outcome of 13 consecutive patients retro-
spectively, of which five, two, and six patients had stage
IVA, IVB, and IVC disease respectively. They received
3-dimensional conformal radiotherapy and chemother-
apy, plus surgery, the median progression-free survival
and overall survival were 2.8 and 3.8 months respect-
ively. Considering that patients with ATC showed poor
prognosis despite multimodality treatment, an effective
mode of treatment warranted further study. Intensity
modulated radiotherapy (IMRT) is an advanced form of
three dimensional conformal radiotherapy, conformingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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a good therapeutic ratio can be achieved. The paper report
the outcomes for the first 13 consecutive patients treated
with IMRTcombined with surgery and chemotherapy.
Methods
The study was approved by our institution’s ethics com-
mittee (Fudan University Shanghai Cancer Center Insti-
tutional Review Board, reference number 090371-5).
We analyzed the outcomes of 13 ATC patients treated
with IMRT in our institution between October 2008
and February 2011. There were 10 males and 3 females,
whose median age was 62 (range, 43-75 years). The
diagnosis of six patients with ATC was based on aspir-
ation biopsy with addition of immunohistochemistry
and the other seven were diagnosed histologically by bi-
opsy or surgery. Five patients had evidence of distant
metastases at presentation. The sites of distant metasta-
ses were lung (3 patients), bone (1 patient), and at mul-
tiple sites (1 patient). The clinical characteristics of the
thirteen patients are listed in Table 1. Initial evaluation
included physical examination, routine labs, computed
tomography (CT) scans of the chest and neck, abdom-
inal ultra-sonography, and bone scintigram. Additional
investigations were performed only on those with suspi-
cious findings. ATC patients can be divided into 3 sub-
groups: (1) stage IVA, a tumor limited to the thyroid
gland; (2) stage IVB, a tumor beyond the thyroid capsule;
and (3) stage IVC, tumors exhibiting distant metastasis.
According to this staging system, of our 13 patiens, 8 were
IVB, and 5 wereIVC (Table 1).
In our institution we have tried IMRT combined with
chemotherapy and/or surgery for these 13 ATC patients.
All patients were treated in the supine position usingTable 1 Patients characteristics
Number of patients (%) 13














KPS: Karnofsky performance status; FNA: fine needle aspiration.thermoplastic mask and received IMRT with 6 MV X
ray. The simulation CT scans were done using 5 mm slices
from the head to the level of diaphragm. Gross tumor vol-
ume (GTV) included the primary tumor and metastatic
lymph nodes found in clinical and imaging examinations.
Clinical target volume (CTV) included thyroid area and
regional lymph nodes, with elective treatment of bilateral
level II through VI and mediastinal lymph nodes to the
level of the carina. High-risk clinical target volume was
defined as thyroid bed plus regional lymph node involved
by tumor. All patients were irradiated 1 fraction daily,
5 days per week. A dose of 66 Gy/33 fractions/6.6 weeks
was prescribed to the planning target volume (PTVg), de-
fined as the GTV plus 0.5 cm margin. A dose of 60 Gy
was prescribed to the high-risk clinical target volume plus
0.5 cm margin. A dose of 54 Gy was prescribed to the
low-risk clinical target volume.
After treatment, patients were follow-up every 3 months
for the first 2 years, then every 6 months for the following
years. All patients were followed until death or time of
analysis. The survival time was determined from the date




Table 2 summarizes the treatment and outcomes of the
13 patients. The median total dose of GTV was 60 Gy
(range, 40-66 Gy). The median overall radiation therapy
treatment time was 42 days (range, 28-49 days), and the
median number of fractions was 30 (range, 20-33 frac-
tions). Nine patients (75%) completed radiotherapy at a
dose ≥ 60 Gy. Two patients gave up radiotherapy due to
dysphagia at dose of 40 Gy and 54 Gy. One month later,
the symptom disappeared, computed tomography (CT)
scan of the two patients demonstrated shrinkage of tumor.
One patient at stage IVC developed enlargement of lung
and head lesion during concurrent radiochemotherapy, al-
though the neck lesion shrunk after 50 Gy. The patient
stopped radiotherapy, and received multi-agent chemo-
therapy (GP) instead. One patient appeared to have head-
ache during IMRT, MRI scan showed brain metastasis and
radiotherapy of thyroid area and regional lymph nodes
was stopped at 58 Gy.
Chemotherapy
Eleven patients received chemotherapy, eight of whom
were given concurrent chemotherapy with cisplatin (DDP)
35 mg/m2/week in six patients, paclitaxel 70 mg/m2/week
in one patient, and paclitaxel 135 mg/m2 on d1 and cis-
platin 25 mg/m2 on d1-3, repeated on day 28 in one pa-
tient. Eight patients were given neoadjuvant or adjuvant
chemotherapy every 3 weeks for 2 cycles. Of these, four
were given gemcitabine and cisplatin, two were given
Table 2 treatment and result




Biopsy + tracheotomy 2(15.4)




Neo + Adj 1(7.7)
Neo + Con 2(15.4)
Con + Adj 2(15.4)

















R0, no residual tumor; R2, macroscopic residual tumor; Neo, neoadjuvant; Con,
concurrent; Adi, adjuvant; CR, complete response; PR, partial response; SD,
stable disease; PD, progressive disease; DM, distant metastasis.
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and fluorouracil and cisplatin in one. The doses for the
drugs are as follows: cisplatin 25 mg/m2 on d1-3, and
gemcitabine 1000 mg/m2 on days 1 and 8, fluorouracil
500 mg/m2, paclitaxel 135 mg/m2, docetaxel 60 mg/m2,
every 3 weeks. Adjuvant chemotherapy with the same
regimen was administered after 28 days after the end of
radiotherapy.Surgery
Surgical intervention included complete resection of cer-
vical nodes in one patient with lung metastasis, partial
resection in one patient, biopsy only in five, and trache-
otomy in two.Toxicities
There were no treatment-related deaths. During IMRT,
mucositis of pharynx and esophagitis were the most com-
mon acute treatment toxicities. All patients developed
mucositis/esophagitis: RTOG grade I in eleven patients
and grade II in two. Six patients needed nutritional sup-
port intravenously for mucosal reaction. The median dur-
ation was 6 days (3 - 9 days), but none of them required
tube feeding support. Radiotherapy was given up in two
patients due to esophagitis (grade II). One month later,
the esophagitis disappeared and the tumor was shown to
have shrunk as seen by CT scan. Main side effects attrib-
uted to chemotherapy were hematological and digestive
toxicity. Grade 3 and 4 neutropenia were observed in
three patients, and grade 3 thrombocypenia was observed
in one. All patients had grade I/II nausea and vomiting.
There was no late adverse effect of therapy (≥ grade II),
such as pneumonitis, esophageal stenosis, fibrosis in neck.
Local control, distant metastasis, and survival
At a median follow-up duration of twelve months (range
2 to 36 months), mean survival was 11 months and me-
dian survival was 9 months. At the latest follow-up, five
patients were alive and have been followed for 8, 8, 12,
15, 36 months, respectively. The locoregional disease
were in complete remission in 2 patients, partial remis-
sion in 1 patient, was stabilized in 7 patients and there
was progressive disease in 3 patients. Distant metastases
were found in seven patients, and the sites were lung (1
patient), bone (1 patient), brain (1 patient) and multiple
sites (4 patients). Eight patients died 2, 4, 7, 8, 9, 9, 12,
and 16 months after treatment respectively. The direct
causes of death were distant metastases (6 patients) and
locoregional failure (2 patients).
Discussion
Anaplastic thyroid carcinoma has a low incidence but is
highly lethal, so there have been no large phase III trials.
The most available evidence is derived from retrospect-
ive series, which suggest that a combination of surgery,
radiotherapy, and chemotherapy may be useful. One
hundred patients with ATC at Ito Hospital in Tokyo be-
tween 1993 and 2009 were reviewed, most of whom
were in stage IVC (58%) and IVB (31%). The 1-year sur-
vival rates of IVB, and IVC were 24.8%, 8.2% respectively
[10]. Derbel O. et al treated 44 patients with ATC
between 1996 and 2010, complete response, partial re-
sponse, and progression after treatment were 31.8%,
18.2%, and 50.0%. The median survival of the 44 patients
was 8 months [11].
It is known that the total radiation dose is related to
local control, and the failure of locoreginal control of
ATC leads to dyspnea, which would need tracheostomy.
Swaak-Kragten AT et al. reported a retrospective study
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for patients who had received a total dose of > 40 Gy
versus ≤ 40 Gy, was 5.4 and 1.7 months, respectively
(P < 0.001) [12]. Another study indicated that median
survival of patients receiving 40 Gy or more (n = 24) was
longer than those with less than 40 Gy (n = 34) (9 vs
3 months) [13]. Compared with 2D, IMRT provides a
more conformal high dose with improved homogeneity to
the gross disease and high-risk areas, while lowering the
dose to normal organs at risk, including spinal cord, epi-
glottis false/true vocal cords, pharyngeal constrictors and
esophagus. Our results compared to other report sup-
ported the hypothesis that IMRT may improve ATC out-
come, especially local control. Foote RL et al reported that
ten patients (40%) had regionally confined ATC (stag IVA
in 7 patients, IVB in 3 patients) were treated by IMRT
combined with individualized surgery (where feasible),
and chemotherapy. The target volume included any re-
sidual cancer within the thyroid bed and/ regional lymph
nodes, with elective treatment of bilateral level II- VI,
mediastinal lymph nodes to the level of the carina, and
received 57.6-70 Gy. Five patients (50%) are alive and
disease-free, and overall survival at 1 and 2 years was 70%
and 60%, respectively [14]. Our preliminary results of
IMRT showed: the tolerance of patients was significantly
improved, almost all patients received higher dose of radi-
ation (> 54 Gy). Only two patients received 40 Gy and
54 Gy respectively and they gave up the radiotherapy be-
cause of esophagitis, but after one month their dysphagia
improved. Another patient with lung metastasis received
50 Gy and stopped concurrent radiochemotherapy (cis-
platin). Instead he was given combined chemotherapy,
the bigger neck mass became smaller and dyspnea was
relieved. Higher dose brought neck mass under control,
76.9% (10/13) patients obtained locoregional control
(including complete and partial response and stable
disease), thus avoiding tracheostomy due to breathing
difficulties, which significantly improved the patient’s
quality of life and survival. The present study of IMRT
in ATC showed an apparent improvement in median
survival of 4-8 months, although the number of patients
in this series is modest.
For patients with ATC, the main causes of death were
failure of local control and distant metastases. Multivariate
analysis demonstrated that age ≥ 70 years, white blood cell
(WBC) ≥ 10,000 mm3, extra-thyroidal invasion, distant
metastases, avoidance of multimodality therapy, and radi-
ation therapy with a dose of < 40 Gy were risk factors for
poorer survival [6,15], but the most direct cause of death
is upper airway obstruction as reported by Tashima L
et al. [5]. In his study of 33 patients, dyspnea was the only
independent factor affecting the survival. For ATC, the
opportunity of complete surgery is rare because of its
extensive invasion and distant metastases. Tracheotomyprocedures have to be performed to resolve dyspnea
caused by compression by the neoplastic mass or bilateral
laryngeal nerve palsy, but it was not shown to significantly
increase survival time and may sacrifice quality of life [5].
In this series of patients treated with IMRT, direct causes
of death were distant metastases (6/8 patients) and locore-
gional progression (2/8 patients). Most of the patients
present at diagnosis with metastatic disease, but almost all
patients developed new metastasis during the rapid course
of the disease. Chemotherapy has been studied for many
years, but it is still unclear as to which systemic therapy is
the best. Over the past few years, the most used agent in
ATC is doxorubicin, cisplatin, 5-fluorouracil, and mitox-
antrone, but the results of these drugs were disappointing.
In recent years, new drugs including paclitaxel, gemcita-
bine have been used to try to increase overall survival in
patients with ATC, but until now they do not seem to
improve the outcomes significantly [16-20]. In ATC pa-
tients reported at stage IVB (n = 9), IVC (n = 4), induction
chemotherapy by weekly paclitaxel is a promising thera-
peutic strategy and responders can be expected to achieve
long-term survival, compared to that of ATC patients at
stage IVB treated without paclitaxel (n = 50). However, no
significant difference of overall survival was observed in
patients at stage IVC patients with or without weekly in-
duction paclitaxel (n = 13) [18]. In our series, cisplatin was
combined with 5-fluorouracil, paclitaxel, and gemcitabine
respectively, but there was no clear correlation between
the specific chemotherapy administered and its outcome.
The main toxicity of radiotherapy was dysphagia and
esophagitis, which may have made patients quit the
radiotheraphy. Five patients with ATC have been treated
at the Tom Baker Cancer Centre, radiation therapy (RT)
was delivered in two phase using a three-dimensional
(3D) conformal technique, 60% of patients needed tube
feeding and 20% required tracheostomy because of dys-
phagia or dyspnea [21]. Troch M et al. reported that a
total of six patients with ATC received standard external
beam RT of 60 Gy in 30 fractions alone with docetaxel,
all patients developed severe esophagitis, which resulted
in inability to swallow food and and thereafter needed
parenteral nutrition. Only three patients received the
planned 60 Gy, other three patients discontinued at 40,
44, and 50 Gy because of side effects [22]. As opposed
to these results, the side effect in our study of IMRT was
mild: none of the patients required tube feeding support
or tracheostomy during radiotherapy. There are limita-
tions with our analyses: the dataset is relatively small
considering the number of variables that were evaluated,
thus limiting the impact of our analyses.
Conclusions
In summary, our consecutive series of stage IVB, and IVC
ATC patients treated with IMRT combined multimodality
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with acceptable toxicity. The main direct cause of death
for ATC patients was distant metastases instead of airway
obstruction. New therapies need further investigation.
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